SAHPRA chief executive Dr Boitumelo Semete-Makokotlela said the product is “the most effective HIV prevention measure thus ...

By William Baloyi When President Donald Trump issued an executive order suspending all foreign aid to South Africa, in ...

The timing of the renewed support is pivotal. South Africa is preparing to roll out Lenacapavir, a groundbreaking long-acting ...

South Africa’s Health Product Regulatory Authority (SAHPRA) has approved the use of the twice-yearly HIV prevention drug, lenacapavir. In a statement released on 27 October, the regulatory body said ...

South Africa has made history by becoming the first African nation to register Lenacapavir, a revolutionary long-acting ...

The South African Health Products Regulatory Authority (SAHPRA) has announced the registration of lenacapavir, making South ...

Camber Pharmaceuticals’ parent company, Hetero, a global company specializing in active pharmaceutical ingredients and ...

Dr Joel Steingo of TB HIV Care says Lenacapavir could be a breakthrough in reducing infections, especially at a time when ...

Lenacapavir is an investigational, long-acting HIV-1 capsid inhibitor designed to inhibit HIV replication at multiple stages of its lifecycle. A New Drug Application (NDA) has been submitted to the ...

South Africa has become the first African country to register lenacapavir, a groundbreaking six-monthly HIV prevention ...

The South African Health Products Regulatory Authority has approved Lenacapavir, a long-acting injection that prevents HIV ...

South Africa advances HIV prevention with the lenacapavir rollout in 2026, and the US approves the PEPFAR Bridge Plan for six months.